About Acacia Pharma
Acacia Pharma is a Healthcare company based in Cambridge (United Kingdom) founded in 2006, and was acquired by Eagle Pharmaceuticals in March 2022. Acacia Pharma has raised $33.5 million across 5 funding rounds from investors including Eagle Pharmaceuticals, Hercules Capital and Cosmo Pharmaceuticals. The company has 74 employees. Acacia Pharma offers products and services including Barhemsys, Byfavo, and APD403. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is ACACIA PHARMA GROUP LIMITED. Its competitors include Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
Developer of therapeutic solutions for treating cancer. Its products include APD405, an injectable formulation of an oral drug for the use of nausea and vomiting; APD209, which is for the use of cancer cachexia; and APD421, an intravenous formulation for the use of prevention and treatment of nausea and vomiting. The company also concentrates its discovery efforts in cancer-related fatigue, cancer cachexia, and xerostomia.
- Headquarters Cambridge, United Kingdom
- Employees 74
- Stage Acquired
- SectorsHealthcare
- Website acaciapharma.com
- Social LinkedIn
- Acquired by Eagle Pharmaceuticals (Mar 2022)
- Legal Name Acacia Pharma Group Limited
- Date of Incorporation 02 Sep, 2015
- Jurisdiction ALTRINCHAM, CHESHIRE, UNITED KINGDOM
- Net Profit-$20.72 M (USD)-151as on Dec 31, 2018
- Total Equity Funding$33.5M (USD)
in 5 rounds
- InvestorsEagle Pharmaceuticals
& 6 more
- Employee Count74
- Acquired byEagle Pharmaceuticals
(Mar 2022)
Products & Services of Acacia Pharma
Acacia Pharma offers a comprehensive portfolio of products and services, including Barhemsys, Byfavo, and APD403.
Treats postoperative nausea and vomiting in patients.
Provides sedation for procedural and surgical use.
Targets oncology treatments for chemotherapy patients.
Funding Insights of Acacia Pharma
Acacia Pharma has successfully raised a total of $33.5M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $33.5M
- Total Rounds 5
- First Round $10M
(Mar 2011)
- Investors Count 6
All 5 funding rounds of Acacia Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2021 | – | Post-IPO | – | – | – |
| Dec 2020 | – | Series B | – | Cosmo Pharmaceuticals | – |
| Jul 2018 | $30M | Debt – Conventional | – | – | |
| Sep 2013 | $23.5M | Series B | – | – | |
| Mar 2011 | $10M | Series A | – | – |
7 investors in total: 7 institutional.
Investors in Acacia Pharma
Acacia Pharma has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Eagle Pharmaceuticals, Hercules Capital and Cosmo Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
Venture capital investment and global platform support for startups. | 2008 | eightroads.com | London, United Kingdom | |
Private equity and venture capital fund focused on the healthcare sector | – | novoholdings.dk | Hellerup, Denmark | |
Private equity and venture captial firm focused on healthcare sectors | – | gildehealthcare.com | Cambridge, United States | |
Life science companies are funded through venture capital investments. | – | lundbeckfonden.com | Copenhagen, Denmark | |
Therapeutics for gastrointestinal diseases are developed and provided. | 1996 | cosmopharma.com | Dublin, Ireland | |
Develops injectable products for use in critical care, orphan diseases, and oncology | 2007 | eagleus.com | Woodcliff Lake, United States |
Investor details for Acacia Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Acacia Pharma
5 people are tracked at Acacia Pharma (5 in leadership); the tracked headcount is 74.
| Name | Role | Group |
|---|---|---|
Gabriel Max Fox | Chief Medical Officer | Leadership |
Johan Kordel | Non Executive Director | Leadership |
Pieter Van De Meer | Non Executive Director | Leadership |
Martin William Edwards | Director | Leadership |
Scott Byrd | Chairman | Leadership |
Complete people profiles for Acacia Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Acacia Pharma
4 dated milestones of Acacia Pharma across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Acacia Pharma is founded.
- Funding First funding round of $10.0M.
- Funding Latest funding round, Post-IPO,.
- Exit Acquired by Eagle Pharmaceuticals.
Competitors of Acacia Pharma
Acacia Pharma has 9 listed competitors in our database, 8 of them funded. They include Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of Acacia Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Acacia Pharma
Websites that share an audience with Acacia Pharma (acaciapharma.com).
Websites whose visitors overlap most with Acacia Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ideapharma.com | 100% | 3.3K | #7,464,235 | View details | |
| traconpharma.com | 100% | – | – | View details | |
| heidelberg-pharma.com | 100% | 3.9K | #1,811,054 | View details | |
| agennix.com | 100% | – | – | View details | |
| phrma.org | 98% | 63.3K | #555,565 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Acacia Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
10 companies that operate in the same segment as Acacia Pharma (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Acacia Pharma
Complete news archive for Acacia Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Acacia Pharma
Acacia Pharma was founded in 2006 and raised its 1st funding round 5 years after it was founded.
Acacia Pharma is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Acacia Pharma is a funded company, having raised a total of $33.5M across 5 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Mar 2011.
Acacia Pharma has 74 employees.
Developer of therapeutic solutions for treating cancer. Its products include APD405, an injectable formulation of an oral drug for the use of nausea and vomiting; APD209, which is for the use of cancer cachexia; and APD421, an intravenous formulation for the use of prevention and treatment of nausea and vomiting. The company also concentrates its discovery efforts in cancer-related fatigue, cancer cachexia, and xerostomia.
Acacia Pharma's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Acacia Pharma offers Barhemsys, Byfavo, and APD403.
Acacia Pharma has 7 investors. Key investors include Eagle Pharmaceuticals, Hercules Capital, Cosmo Pharmaceuticals, Eight Roads Ventures, and Novo Holdings.
Acacia Pharma operates through Acacia Pharma Group Limited.
Yes. Acacia Pharma was acquired by Eagle Pharmaceuticals in March 2022.